Tag: cdx

Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

– Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) – – New patent granted for PRA023 companion diagnostic (CDx) reinforces Prometheus’ precision approach and extends CDx patent coverage into 2040 – – Company to present today…

Continue Reading Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare … | News

Very important pharmacogene variants in the Blang population

Introduction The use of drugs should be different among diverse ethnic groups because of differences in ethnicity, age, sex, environmental factors and genetic factors. If these differences are ignored, then drug sensitivity, metabolic rate, and adverse reactions are affected, which influences the curative effect of drugs and aggravates the illness…

Continue Reading Very important pharmacogene variants in the Blang population

Establishment of sunitinib-resistant CDX model of ccRCC

Introduction Renal cell carcinoma (RCC) accounts for approximately 2–3% of all malignant tumors, and its prevalence is rising. Metastatic RCC accounts for 25–30% of all RCC cases, and has an exceedingly poor prognosis.1 In 2020, among approximately 430,000 newly discovered cases of RCC, 179,000 died.2 Clear cell renal cell carcinoma…

Continue Reading Establishment of sunitinib-resistant CDX model of ccRCC

Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

NEW YORK – Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo’s investigational DB102 treatment for diffuse large B-cell lymphoma. Under the agreement, Qiagen will develop an…

Continue Reading Qiagen, Denovo Biopharma to Develop Liquid Biopsy CDx Test for Investigational Lymphoma Treatment

Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. QIAGEN (NYSE: QGEN) and Denovo Biopharma LLC today announced a collaboration to develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who…

Continue Reading Qiagen (QGEN) Collaborates with Denovo to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

– QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102 – The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. SAN DIEGO and…

Continue Reading Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102TM The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. New master collaboration agreement adds…

Continue Reading QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Fidler Breaks Down the Steps for Targeted Treatments in Metastatic NSCLC

Oncologists discuss a 59-year-old man with poorly differentiated adenocarcinoma of the lung. During a Targeted OncologyTM Case-Based Roundtable event, Mary Jo Fidler, MD, associate professor, Division of Hematology, Oncology, and Cell Therapy, Rush Medical College, discussed a 59-year-old man with non–small cell lung cancer. SHAH: I do next-generation sequencing [NGS]…

Continue Reading Fidler Breaks Down the Steps for Targeted Treatments in Metastatic NSCLC

Sr. Bioinformatics Scientist, Algorithm Development (Remote Option) at Guardant Health

Company Description Company Description: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs…

Continue Reading Sr. Bioinformatics Scientist, Algorithm Development (Remote Option) at Guardant Health

Precision Oncology: Advancing the Development of Liquid Biopsy-Based Diagnostics with NGS

Precision oncology leverages molecular information about cancer to personalize therapy and improve outcomes. The discovery and development of relevant biomarkers is a prerequisite to fulfillment of the promise of precision oncology, but the challenge for researchers is that clinically actionable mutations occur at very low frequency and sourcing biospecimens with…

Continue Reading Precision Oncology: Advancing the Development of Liquid Biopsy-Based Diagnostics with NGS

FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

1. Ross JS, Wang K, Javle MM et al. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. J Clin Oncol 2015;33:40009. doi.org/10.1200/jco.2015.33.15_suppl.4009. Article  Google Scholar  2. Goyal L, Govindan A, Sheth RA et al. Prognosis and clinicopathologic features of patients…

Continue Reading FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Published: Oct. 20, 2021 at 10:30 AM EDT|Updated: 8 hours ago — New Tool for Detection of Minimal Residual Disease in Acute Myeloid Leukemia to Better Help in Fight Against Cancer — BALTIMORE, Oct. 20, 2021 /PRNewswire/ — Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the…

Continue Reading New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal(TM) Blood Test to Predict Recurrence Across Early-Stage Cancers | 2021-10-05 | Press Releases

1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-patient prospective, observational, multi-center study designed to evaluate the performance of…

Continue Reading Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal(TM) Blood Test to Predict Recurrence Across Early-Stage Cancers | 2021-10-05 | Press Releases

Biomarker Testing in MBC Management: ‘Essential’

Identifying biomarkers in metastatic breast cancer (MBC) has become an integral part of choosing treatments and understanding disease progression. The American Society of Clinical Oncology Clinical Practice Guideline, published in 2015, recommends an initial biopsy to confirm estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2…

Continue Reading Biomarker Testing in MBC Management: ‘Essential’

Advancing Liquid Biopsy Companion Diagnostics with a Novel Sequencing Initiative

Sponsored content brought to you by   The promise of precision oncology is being realized, with an array of targeted treatments and immunotherapies now available across a spectrum of cancer and other indications. Genomic insights have played a critical role in advancing our understanding of cancer biology and driving the…

Continue Reading Advancing Liquid Biopsy Companion Diagnostics with a Novel Sequencing Initiative

Sr. Bioinformatics Scientist, Algorithm Development (Remote Option) at Guardant Health, Inc.

Company DescriptionCompany Description: Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across…

Continue Reading Sr. Bioinformatics Scientist, Algorithm Development (Remote Option) at Guardant Health, Inc.

Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

NEW YORK – Chinese genomic testing firm Genetron Health said Monday that it has partnered with Impact Therapeutics to support the firm’s anti-cancer drug development efforts. The two companies plan to work together to discover new targets and develop companion diagnostics for a class of drugs called synthetic lethal inhibitors,…

Continue Reading Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development

Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

NEW YORK – At the European Society for Medical Oncology Congress this week, precision oncology assay developer Lucence presented data that demonstrated its amplicon-based LiquidHallmark assay could be used to personalize care for people with advanced urothelial carcinoma. LiquidHallmark is a laboratory-developed test based on the company’s AmpliMark next-generation sequencing platform…

Continue Reading Data Demonstrates Lucence Liquid Biopsy Test Can Track Treatment-Based ctDNA Changes

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership

NEW YORK – Molecular Health said Wednesday that is collaborating with South Korea’s Eone-Diagnomics Genome Center to create a combined offering for precision oncology testing. Specifically, the companies are pairing Molecular Health’s MH Guide software and EDGC’s OncoCatch-CDx assay, which analyzes circulating tumor DNA using next-generation sequencing in-house bioinformatics. A joint…

Continue Reading Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership

Produce PCA bi-plot for 1000 Genomes Phase III

Note1 – Previous version: Produce PCA bi-plot for 1000 Genomes Phase III in VCF format (old) Note2 – this data is for hg19 / GRCh37 Note3 – GRCh38 data is available HERE The tutorial has been updated based on the 1000 Genomes Phase III imputed genotypes. The original tutorial was…

Continue Reading Produce PCA bi-plot for 1000 Genomes Phase III

How to convert .mol files to cdx?

How to convert .mol files to cdx? 0 Now I have many .mol files, I want to convert them to .cdx files, cdx is a format of chemdraw, How can I do this programmatic, Thanks. convert mol cdx chemdraw • 13 views Source link

Continue Reading How to convert .mol files to cdx?